Fusen Pharmaceutical Company Limited (1652.HK)

HKD 0.3

(13.46%)

Gross Profit Summary of Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical Company Limited's latest annual gross profit in 2023 was 299.5 Million CNY , up 33.1% from previous year.
Fusen Pharmaceutical Company Limited's latest quarterly gross profit in 2024 Q2 was 52.93 Million CNY , down 0.0% from previous quarter.
Fusen Pharmaceutical Company Limited reported a annual gross profit of 225.02 Million CNY in annual gross profit 2022, up 6.58% from previous year.
Fusen Pharmaceutical Company Limited reported a annual gross profit of 211.13 Million CNY in annual gross profit 2021, down -20.65% from previous year.
Fusen Pharmaceutical Company Limited reported a quarterly gross profit of 52.93 Million CNY for 2024 Q1, down -12.06% from previous quarter.
Fusen Pharmaceutical Company Limited reported a quarterly gross profit of 89.55 Million CNY for 2023 Q1, up 23.28% from previous quarter.

Annual Gross Profit Chart of Fusen Pharmaceutical Company Limited (2023 - 2015)

Historical Annual Gross Profit of Fusen Pharmaceutical Company Limited (2023 - 2015)

Year	Gross Profit	Gross Profit Growth
2023	299.5 Million CNY	33.1%
2022	225.02 Million CNY	6.58%
2021	211.13 Million CNY	-20.65%
2020	266.06 Million CNY	25.22%
2019	212.48 Million CNY	-15.45%
2018	251.31 Million CNY	-0.25%
2017	251.94 Million CNY	13.39%
2016	222.18 Million CNY	28.23%
2015	173.27 Million CNY	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	52.93 Million CNY	0.0%
2024 Q1	52.93 Million CNY	-12.06%
2023 Q1	89.55 Million CNY	23.28%
2023 Q4	60.19 Million CNY	0.0%
2023 FY	299.5 Million CNY	33.1%
2023 Q2	89.55 Million CNY	0.0%
2023 Q3	60.19 Million CNY	-32.79%
2022 Q1	39.86 Million CNY	-14.17%
2022 FY	225.02 Million CNY	6.58%
2022 Q3	72.64 Million CNY	82.22%
2022 Q2	39.86 Million CNY	0.0%
2022 Q4	72.64 Million CNY	0.0%
2021 Q2	59.11 Million CNY	0.0%
2021 Q3	46.45 Million CNY	-21.42%
2021 FY	211.13 Million CNY	-20.65%
2021 Q4	46.45 Million CNY	0.0%
2021 Q1	59.11 Million CNY	-11.26%
2020 Q4	66.61 Million CNY	0.0%
2020 Q2	66.41 Million CNY	0.0%
2020 FY	266.06 Million CNY	25.22%
2020 Q1	66.41 Million CNY	25.71%
2020 Q3	66.61 Million CNY	0.3%
2019 FY	212.48 Million CNY	-15.45%
2019 Q4	52.83 Million CNY	0.0%
2019 Q3	52.83 Million CNY	-1.08%
2019 Q2	53.41 Million CNY	0.0%
2019 Q1	53.41 Million CNY	4.25%
2018 Q3	51.23 Million CNY	-31.17%
2018 Q4	51.23 Million CNY	0.0%
2018 Q1	74.42 Million CNY	-3.74%
2018 Q2	74.42 Million CNY	0.0%
2018 FY	251.31 Million CNY	-0.25%
2017 Q1	63.87 Million CNY	10.25%
2017 FY	251.94 Million CNY	13.39%
2017 Q4	77.32 Million CNY	0.0%
2017 Q2	63.87 Million CNY	0.0%
2016 Q1	55.54 Million CNY	0.0%
2016 Q4	57.93 Million CNY	0.0%
2016 FY	222.18 Million CNY	28.23%
2016 Q2	55.54 Million CNY	0.0%
2015 FY	173.27 Million CNY	0.0%
2015 Q3	43.31 Million CNY	0.0%
2015 Q4	55.54 Million CNY	28.23%
2015 Q2	43.31 Million CNY	0.0%
2015 Q1	43.31 Million CNY	0.0%
2014 Q4	43.31 Million CNY	0.0%

Peer Gross Profit Comparison of Fusen Pharmaceutical Company Limited

Name	Gross Profit	Gross Profit Difference
Pak Fah Yeow International Limited	167.43 Million HKD	-78.878%
Grand Pharmaceutical Group Limited	6.52 Billion HKD	95.409%
Extrawell Pharmaceutical Holdings Limited	28.77 Million HKD	-940.71%
Wai Yuen Tong Medicine Holdings Limited	394.81 Million HKD	24.14%
Qianhai Health Holdings Limited	-35.6 Million HKD	941.238%
Lee's Pharmaceutical Holdings Limited	551.31 Million HKD	45.674%
Essex Bio-Technology Limited	1.53 Billion HKD	80.543%
Tongfang Kontafarma Holdings Limited	471.29 Million HKD	36.45%
PuraPharm Corporation Limited	216.62 Million HKD	-38.258%
SSY Group Limited	3.48 Billion HKD	91.416%
JBM (Healthcare) Limited	319.41 Million HKD	6.233%
Jacobson Pharma Corporation Limited	620.47 Million HKD	51.73%
China Resources Pharmaceutical Group Limited	43.36 Billion HKD	99.309%